Mass spectrometry platform could shrink cancer drug discovery cycle to four hours (opens in new tab)

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.